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Abstract
Soluble extracellular proteins usually do not enter the endogenous human leukocyte antigen (HLA) I–dependent
presentation pathway of antigen-presenting cells, strictly impeding their applicability for the re-stimulation of protein-
specific CD8
+ cytotoxic T lymphocytes (CTL). Here we present for the Epstein-Barr virus (EBV) BZLF1 a novel strategy that
facilitates protein translocation into antigen-presenting cells by its solubilisation in high molar urea and subsequent pulsing
of cells in presence of low molar urea. Stimulation of PBMC from HLA-matched EBV-seropositive individuals with urea-
treated BZLF1 but not untreated BZLF1 induces an efficient reactivation of BZLF1-specific CTL. Urea-treated BZLF1 (uBZLF1)
enters antigen-presenting cells in a temperature-dependent manner by clathrin-mediated endocytosis and is processed by
the proteasome into peptides that are bound to nascent HLA I molecules. Dendritic cells and monocytes but also B cells can
cross-present uBZLF1 in vitro. The strategy described here has potential for use in the development of improved
technologies for the monitoring of protein-specific CTL.
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Introduction
Cytotoxic CD8
+ T lymphocytes (CTL) play a key role in the
immunological control of persistent intracellular pathogens and
tumors.CTLspecificallytarget infectedcellsthrough therecognition
of peptides, which are displayed by surface exposed HLA class I
molecules. In most cell types, HLA class I-associated peptides are
generally derived from intracellularly synthesized proteins. For the
processing in the endogenous antigen presentation pathway,
peptides are generated by the proteasome and translocated by the
transporter associated with antigen processing (TAP) to the lumen of
the endoplasmicreticulum,wheretheyaretrimmed andloaded onto
HLA class I molecules [1–3]. The resulting complexes of mature
HLA class I molecules and peptides are transported through the
secretory pathway for display on the cell surface, where they can
interact with CTL. In contrast, exogenous soluble antigens are
typically internalized by antigen-presenting cells (APC) via the
endosomal route, proteolytically fragmented in acidic endosomal
compartments and loaded onto HLA class II molecules to produce a
maturecomplex,which iscapable of interacting with CD4
+ T helper
(Th) cells. However, APC have the capacity to internalize pathogens
as well as infected and abnormal cells from their environment and
direct them to the endogenous HLA class I processing machinery by
a process termed cross-presentation. Efficient cross-presentation of
exogenous antigens is achieved by dendritic cells and macrophages
[4–6], but also by B cells [7], endothelial cells [8] and neutrophils [9]
via various routes for antigen delivery from endosomes and
phagosomes to the cytosol [10,11] or by direct processing of
captured antigens in intracellular vesicles or at the plasma
membrane [10,12,13]. Yet, evidence for the stimulation of CTL
by soluble exogenous proteins is scarce.
The developmentofproteindeliverysystems for APCisone of the
main challenges in T cell diagnostics, vaccinology and cellular
therapy. Current strategies include intracellular synthesis of foreign
antigens by infection of APC with microbial live vectors or
transfection with expression vectors and RNA [14,15]. In addition,
coupling of antigens to micro beads [16], antibodies [17,18], lipids
[19], heat shock proteins [20] and arginine-rich protein transduction
domains (PTD) [21] confers delivery to the HLA class I processing
machinery. However, a variety of practical and theoretical concerns,
such as restrictions in the translocation of individual antigens, the
lack of biological inertness of the transfer vectors and/or difficulties
with the preparation and use of more complex experimental systems
precludeversatileapplicationsindiagnostics,therapyandprevention
of infectious diseases and tumors.
Here we demonstrate a substantial improvement of HLA class
I-dependent antigen presentation to CTL by urea treatment,
which facilitates an efficient antigen translocation to the
endogenous cytosolic processing pathway.
Results
Urea-adjuvated soluble EBV BZLF1 specifically stimulates
CTL
Soluble extracellular proteins are almost exclusively processed
by the exogenous pathway for presentation on HLA class II
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CTL responses [22,23]. Here we investigated, whether the
denaturation of protein in a high molar urea solution and its
subsequent incubation with APC in the presence of low
concentrations of urea mediates an improved protein delivery
into the endogenous antigen processing and presentation pathway.
As a model antigen we used the EBV BZLF1 protein, since it
has been previously described to harbor an immunodominant B8-
restricted CTL epitope termed RAK [24], thus offering a suitable
read-out system for the detection of BZLF-specific CTL reponses.
Heparinized whole blood obtained from HLA B8-positive EBV-
positive individuals was stimulated with either 10 mg/ml urea-
adjuvated BZLF1 (uBZLF1) or dialyzed urea-free BZLF1, while
the synthetic RAK peptide and a 0.04 M urea solution served as
positive and negative controls, respectively. Exposure of blood cells
with uBZLF1 induced the reactivation of substantial numbers of
CTL as shown by intracellular IFN-c staining, which was not seen
in cells stimulated with BZLF1 or 0.04 M urea (Fig. 1), even after
prolongued incubation times (data not shown). In addition, the
frequencies and ratios of specifically reactivated CTL upon
stimulation with uBZLF1 and the RAK peptide differed
significantly in blood samples of individual donors. The removal
of urea from uBZLF1 by extensive dialysis resulted in an almost
complete loss of its capacity to stimulated CD8
+ T cells.
Furthermore, we observed only low or undetectable numbers of
IFN-c producing CD4
+ Th cells in response to stimulation with
uBZLF1 (Fig. S1). Comparable results were achieved using
recombinant cytomegalovirus (CMV) pp65 protein (Miltenyi
Biotec). Urea-formulated pp65 (upp65) but not urea-free dialyzed
pp65 induced significant reactivation of pp65-specific CTL,
whereas removal of urea did not significantly influence the
capacity of (u)pp65 to restimulate CD4
+ T cells (Fig. S2). Dose
titration studies with urea revealed no significant cytotoxic effects
at concentrations of 0.04 M urea present in uBZLF1-stimulated
peripheral blood mononuclear cells (PBMC) (Fig. 2). Beyond that,
the applied urea solution did neither induce the secretion of
cytokines from PBMC (Fig. S3) nor activate immature dendritic
cells for the upregulation of costimulatory (CD80, CD83 and
CD86) and MHC class-II molecules (Fig. S4). These data indicate
that urea formulation mediates an efficient transfer of EBV BZLF1
into the endogenous HLA class I presentation pathway.
Transfer of uBZLF1 to the HLA class I presentation
pathway is not mediated by a PTD-like domain within
the C-terminal region of BZLF1
During the last decade short arginine-rich protein-transduction
domains (PTD) have been described to mediate polypeptide
translocation across cell membranes. Sequence alignments revealed
the presence of an arginine-rich domain within the C-terminal
region of BZLF1 exhibiting similarities to a known PTD domain of
the Antennapedia (Antp) homeoprotein (Fig. 3A). To examine the
role of this PTD-like domain in the translocation of uBZLF1 into
APC, we expressed a deletion mutant (BZLF1D176–189), lacking the
putative PTD in E. coli (Fig. 3B). We stimulated PBMC of HLA B8-
positive EBV-seropositive healthy donors with either 10 mg/ml
uBZLF1 or truncated uBZLF1D176–189 and determined the number
of specifically restimulated, IFN-c secreting T cells by ELISpot.
PBMC stimulated with HIV Gag-derived peptide E10F served as
negative control. In these experiments, uBZLF1 and uBZLF1D176–
189 showed no significant differences in their capacity to reactivate
BZLF1-specific T cells (Fig. 3C), indicating that the predicted PTD
within BZLF1 plays no significant role in urea-mediated protein
translocation into the endogenous processing pathway of APC.
uBZLF1 enters APC via a cross-presentation pathway
We used specific inhibitors of the HLA class I processing and
presentation pathway to evaluate the molecular mechanisms
underlying the urea-mediated uptake, processing and presentation
of BZLF1. In order to study the energy dependency of uBZLF1
uptake into APC, PBMC were pre-incubated for 45 min at 4uCo r
37uC and subsequently pulsed at the same temperature with
uBZLF1 or the RAK peptide for an additional two hours. After
removal of excessive antigen by washing, cells were incubated for
an additional 20 h at 37uC and the numbers of IFN-c producing T
cells were determined by ELISpot. Pre-incubation and pulsing of
cells with uBZLF1 at 4uC resulted in significantly reduced
numbers of IFN-c producing T cells compared to PBMC pulsed
at 37uC, indicating a temperature sensitive and thus energy-
dependent uptake of uBZLF1. In contrast, the efficiency of CTL
reactivation by the RAK peptide was independent of the pre-
incubation and pulsing temperature (Fig. 4A).
To further analyze the internalization process of uBZLF1,
PBMC were pre-treated and stimulated for 20 h with uBZLF1 or
RAK peptide in the presence of sucrose, an inhibitor of clathrin-
mediated endocytosis. Specific activation of CTL by uBZLF1-
pulsed PBMC was substantially abrogated in a dose dependent
manner by sucrose, while CTL activation by the RAK peptide was
hardly affected (Fig. 4B). Herein, sucrose did not exhibit cytotoxic
effects on PBMC at the used concentrations, as shown by
propidium iodide (PI) staining. These results indicate an uptake
of uBZLF1 by clathrin-mediated endocytosis.
To examine the role of proteolytic processes within endolyso-
somal compartments in the processing of uBZLF1 for epitope
presentation on HLA class I molecules, we pre-treated PBMC for
45 min with two inhibitors of lysosomal acidification, NH4Cl or
chloroquine [25,26], and subsequently stimulated cells for an
additional 20 h with uBZLF1 or RAK peptide in presence of the
indicated inhibitors. Treatment of PBMC of HLA B8-positive,
EBV-seropositive donors with both inhibitors did not significantly
influence the capacity of uBZLF1 and the RAK peptide to
specifically stimulate T cells for IFN-c production, strongly
Author Summary
CD8
+ T lymphocytes (CTL) play a key role in the
immunological control of persistent intracellular pathogens
and tumors. Thus, the development of improved technol-
ogies for the monitoring and expansion of protein-specific
CTL represents a major challenge in clinical immunology.
CTL specifically target infected cells through the recognition
of peptides displayed by surface exposed HLA class I
molecules. In most cell types, HLA class I–associated
peptides are generally derived from cytosolic proteins. In
contrast, delivery of soluble exogenous proteins to the
endogenous HLA class I processing pathway is scarce. Here
we exemplified with the Epstein-Barr virus immediate early
protein BZLF1 a novel and simple urea-based strategy to
deliver soluble proteins to the class I processing pathway of
antigen-presenting cells by cross-presentation. We showed
that urea formulated BZLF1 but not urea-free BZLF1 reveals
a strong capacity to reactivate CD8
+ T cells in blood cells of
EBV-positivedonors. Accordingly, dendritic cells, monocytes,
but also B cells are able to cross-present BZLF1-derived
epitopes to CTL. This technology could improve the
development of T cell diagnostics for microbial diseases
and may facilitate a novel strategy for the expansion of
protein-specific CTL for therapeutic application.
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role in the generation of HLA class I presentable epitopes (Fig. 5A).
To analyze the involvement of the proteasome in the
degradation of uBZLF1, PBMC of EBV-seropositive donors were
cultured and stimulated with uBZLF1 or the RAK peptide for
20 h in the presence of epoxomicine or lactacystine, both
inhibitors of proteasomal proteases. These substances caused
substantial impairment of uBZLF1-mediated CTL activation, with
lactacystine showing a stronger inhibitory effect than epoxomycine
(Fig. 5B). In contrast, both compounds showed no significant
Figure 1. Urea-treated BZLF1 (uBZLF1) but not untreated BZLF1 restimulates specific CD8
+ cytotoxic T lymphocytes. Whole blood
from an EBV-seropositive, HLA B8-positive donor was stimulated with either 10 mg/ml of BZLF1 or uBZLF1 and as controls with 10 mg/ml of RAK
peptide and 0.04 M urea. Cells were incubated at 37 Cu for 7 h with 10 mg/ml BFA added for the last 4 h. Shown is the percentage of CD3
+CD8
+ or
CD3
+CD4
+ cells expressing IFN-c from a representative stimulation of eight independent experiments using a total of 4 different donors. Plots show
log fluorescence intensity.
doi:10.1371/journal.ppat.1000198.g001
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peptide. These results demonstrate that processing of uBZLF1
requires proteolytic activities from the proteasome complex.
Subsequently, we determined the sensitivity of HLA class I
presentation of uBZLF1-derived epitopes to brefeldin A (BFA), an
inhibitor of anterograde endoplasmic reticulum-golgi transport
and hence an inhibitor of the endogenous HLA class I
presentation pathway. Therefore, we pre-incubated whole blood
of EBV-seropositive, HLA B8-positive donors with BFA for
45 min prior to stimulation with uBZLF1, the RAK control
peptide or a 0.04 M urea solution for additional 7 h and analyzed
the frequency of specifically reactivated CTL by intracellular IFN-
c staining. BFA significantly abrogated uBZLF1-induced reacti-
vation of specific T cells, whereas activation of CTL by the RAK
peptide was not significantly influenced (Fig. 5C), implicating that
newly synthesized HLA class I molecules are required for an
efficient presentation of uBZLF1-derived peptides. Taken togeth-
er, these observations strongly suggest that the capacity of uBZLF1
to restimulate specific CTL relies on the uptake and processing of
the antigen via a cross-presentation pathway.
Dendritic cells, monocytes and B cells are capable of
cross-presenting uBZLF1
We analyzed different subpopulations of APC for their ability to
cross-present epitopes from uBZLF1. Therefore monocyte-derived
immature (iDC) and mature DC (mDC), as well as monocytes and
B cells were generated from PBMC of HLA B8-positive
individuals, pulsed with uBZLF1, washed extensively and co-
cultured with autologous PBMC. Activation of T cells was assessed
by IFN-c ELISpot. APC pulsed either with RAK or E10F peptides
served as positive and negative controls. Dendritic cells pulsed with
uBZLF1 showed a higher ability to restimulate antigen-specific T
cells than monocytes and B cells. DC loaded with uBZLF1 were
more efficient in the restimulation of IFN-c producing T cells than
DC incubated with the RAK peptide, while the opposite effect was
observed for monocytes and B cells (Fig. 6). These results indicate
that various APC subpopulations may account for cross-presen-
tation of uBZLF1 and subsequent reactivation of BZLF1-specific
T cells in PBMC or whole blood cultures.
Discussion
In the present study we exemplified with the EBV immediate
early protein BZLF1 a novel technology for the translocation of
exogenous, soluble proteins into the HLA class I processing and
presentation pathway of APC, which relies on the solubilisation of
proteins with high molar urea and incubation of cells with these
antigens in presence of low molar urea. In this study, we used
BZLF1 as model antigen, because it includes an immunodominant
HLA B8-restricted CTL epitope in addition to T helper cells
epitopes [24,27]. In addition, numbers of BZLF1-specific CTL are
known to remain readily detectable over a long period of time,
whereas specific T helper (Th) cell frequencies rapidly decline and
persist at a low level following an acute infection [28].
In vitro stimulation of lymphocytes from HLA B8-positive, EBV-
seropositive individuals with urea-solubilized BZLF1 revealed its
strong capacity to restimulate BZLF1-specific CTL in addition to
low numbers of IFN-c producing Th cells. In some of the tested
individuals, uBZLF1 specifically reactivated higher numbers of
CTL than the RAK peptide. This finding can be explained by the
activation of CTL with specificity for additional CTL epitopes
within BZLF1 (manuscript in preparation).
Similar to uBZLF1 urea-formulated recombinant CMV pp65
protein revealed an enhanced capacity to reactivate pp65-specific
CD8
+ T cells when compared to dialyzed, urea-free pp65
supporting the applicability of the urea-based strategy for proteins
other than BZLF1.
The transfer of uBZLF1 into the HLA class I processing and
presentation pathway was shown to be mediated by urea as
BZLF1 purified from urea by extensive dialysis lost its capacity to
reactivate BZLF1-specific CTL.
Unlike native EBV EBNA1 protein, which has been shown to
enter the endogenous presentation pathway of dendritic cells and
EBV lymphoblastoid cell lines (LCL) upon elongated exposure of
12 hours [29,30], urea-free BZLF1 did not activate CD8
+ T cells
even after 20 hours of incubation. The molecular mechanisms
underlying urea-mediated translocation of BZLF1 are still unclear.
One possible explanation would be, that urea-denaturated
proteins may translocate more efficiently than correctly folded
proteins.
Dowdy and co-workers showed that complete denaturation in
8 M urea and subsequent removal of urea by ionic exchange
chromatography or dialysis strongly enhances the translocation
efficiency of some proteins linked to the PTD of the HIV Tat
protein [31]. However, we showed that removal of urea from urea-
denatured BZLF1 drastically abrogated its capacity to enter the
endogenous processing pathway of APC.
Urea in the applied concentration revealed neither cytotoxic
nor immune activating properties in cultured blood cells and
immature dendritic cells, ruling out the possibility of unspecific
activation of APC or T lymphocytes. Thus, effectiveness of urea
formulation considerably differs from that of uric acid, which
promotes the capacity of co-applied proteins to prime CTL
responses by the stimulation of dendritic cell maturation [32,33].
BZLF1 contains a stretch of basic amino acid residues bearing
resemblance to the PTD of Antp [34]. Several reports have
demonstrated that PTD are able to transfer exogenous proteins
across biological membranes into the cytosol of cells [21,35,36].
Initially discovered in the Tat protein of HIV [21] and in the
Drosophila melanogaster Antp protein [37], these domains share
clusters of basic amino acid residues, most commonly arginines,
which mediate protein translocation into target cells. After binding
of PTD to heparan sulfate on cell surfaces, APC internalize these
proteins efficiently by macropinocytosis [38,39]. Yet, deletion of
this domain from BZLF1 had no significant influence on the urea-
mediated transfer of BZLF1 into the HLA class I processing
pathway, indicating that the arginine-rich domain of BZLF1 does
not play a causal role in the cross-presentation of uBZLF1.
Figure 2. Residual urea in uBZLF1 pulsed cell cultures reveals
no significant cytotoxic effect on lymphocytes. PBMC of two
healthy adult individuals, indicated by the light and dark grey bars,
were incubated with increasing concentrations of urea. Cell viability was
determined after 20 h by propidium iodide (PI) staining.
doi:10.1371/journal.ppat.1000198.g002
Urea-Mediated Cross-Presentation
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sensitive process, suggesting that the antigen is internalized by
endocytosis, phagocytosis or macropinocytosis [40,41] rather than
direct penetration across the lipid bilayer. This assumption is
further supported by the finding that cross-presentation of
uBZLF1 is dose dependently abrogated in presence of sucrose,
strongly suggesting that internalization of uBZLF1 occurs by
clathrin-mediated endocytosis [42]. However, it is likely that
uBZLF1 is rescued from endolysosomal degradation by release
into the cytoplasm or to less acidic compartments, as cross-
presentation of uBZLF1 is neither sensitive to chloroquine nor
NH4Cl, two drugs known to prevent endosomal acidification. As
an alternative pathway uBZLF1 might be transferred to the
endoplasmic reticulum by retrograde transport pathways as
previously described for the B fragment of shiga toxin [43]. The
cellular transport pathway that facilitates the escape of uBZLF1
from destruction by lysosomal proteases remains unclear, since no
well-defined mechanisms have been described for the transfer of
endocytic structures to the cytosol.
However, the impairment of uBZLF-induced CTL activation
by epoxomicine and lactacystine, two inhibitors of proteasomal
proteases clearly demonstrates the translocation of uBZLF1 to the
cytosol and the essential role of the proteasome in the generation
of uBZLF1-derived CTL epitopes.
Figure 3. Deletion of a C-terminal arginine-rich domain within BZLF1 with homology to PTD does not abrogate the capacity of
uBZLF1 to activate specific T cells. (A) A truncated BZLF1 protein, engineered by deletion of the arginine-rich domain (BZLF1D176–189) was
expressed in E. coli, purified and treated with urea as described in materials and methods. (B) The purity of BZLF1 and BZLF1D176–189 was assessed by
Coomassie staining. (C) PBMC of healthy EBV-seropositive donors were stimulated for 20 h with 10 mg/ml uBZLF1, BZLF1D176–189 or the HIV control
peptide E10F and the frequencies of IFN-c producing cells were assayed by ELISpot. The data show mean spot forming cell (SFC) values6standard
deviation (s.d.) of 5 replicate stimulations and are a representative of results performed with PBMC of 3 different individuals.
doi:10.1371/journal.ppat.1000198.g003
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a peptide-loaded HLA class I complex with specific T cell
receptors. Our study shows that processed peptides are loaded
onto new synthesized HLA class I molecules, as re-stimulation of
BZLF1-specific CTL is completely abrogated in presence of BFA,
a known inhibitor of protein secretion. Combined with our
inhibition experiments of the proteasome this finding excludes the
possibility of peptide loading on recycling HLA class I molecules in
endolysosomal compartments [13]. Furthermore, these results rule
out extracellular processing and loading of BZLF1 peptides on
HLA molecules, as previously shown for HLA class II-restricted
epitopes in immature dendritic cells [44].
Cross-presentation is a feature especially described for DC [11]
and monocytes [4]. The ability of B cells to mediate cross-
presentation is discussed controversial [45–47]. Our results showed
that uBZLF1 is mainly cross-presented by iDC and mDC, while
monocytes and B cells displayed reduced capacity to cross-present
uBZLF1. The fact that both iDC and mDC are equally capable of
cross-presenting uBZLF1 seems to be surprising, regarding their
differentcapacitytocaptureantigensbyphagocytosisandpinocytosis
[48]. Yet, this finding supports our previous hypothesis of the cellular
uptake of uBZLF1 by endocytosis, as this internalization route is not
affected by the maturation state of DC [49].
Taken together, the data presented in this study reveal that the
urea adjuvation technology constitutes a simple and useful tool for
the concurrent ex vivo re-activation of antigen-specific CTL and Th
cells. Compared to peptides the use of full length proteins provides
the advantage of independence of HLA restriction. To circumvent
this limitation large numbers of overlapping peptides would have
to be synthesized. Another advantage of full length proteins is a
natural processing of antigenic peptides and even spliced epitopes
could be generated by this means [50]. Therefore this technology
could improve the development of T cell diagnostics in a variety of
viral, cancer and autoimmune diseases and may facilitate a novel
strategy for the expansion of protein-specific CD8
+ T cells for
therapeutic applications.
Materials and Methods
Synthetic peptides and recombinant proteins
The synthetic peptide RAK, representing a HLA B8-restricted
CTL epitope within EBV BZLF1 (aa190–197) [24] and the
control peptide E10F, covering a murine CTL epitope within the
p24 capsid region of HIV-1(BH10) Gag (aa291–300) [51] were
purchased from Synpep and reconstituted at 10 mg/ml in
dimethylsulfoxide. Recombinant CMV pp65 protein was pur-
chased from Miltenyi Biotec, Bergisch Gladbach, Germany.
Expression and purification of BZLF1 and BZLF1D176–189
The open reading frame encoding the cDNA (+1-735, 245 amino
acids)ofEBVBZLF1wasinsertedintothepET5aplasmid(Novagen)
using the EcoRI and BamHI sites. For generation of a plasmid
encoding BZLF1D176–189, nucleotides 525–567 were removed by
deletion PCR. The resulting plasmids were called pET5a-Z and
pET5a-ZD176–189, respectively. For the production of BZLF1 and
BZLF1D176–189, E. coli BL21-DE3/CP-RIL were transformed with
the pET5c-Z or pET5a-ZD176–189 vectors, grown at 26uCt oa n
O.D.600 of 0.8 and induced overnight with 1 mM IPTG. Full-length
BZLF1 was expressed at 26uC for 20 h, truncated BZLF1 variant was
expressed for 3 h at 37uC. Cells were harvested by centrifugation
(10,000 g, 10 min) and stored at 280uC until further processing.
Full-length BZLF1 was solubilized with urea from inclusion bodies,
whereas truncated BZLF1 mutant was expressed in a soluble form
and urea-denatured during purification process.
Figure 4. Uptake of uBZLF1 occurs in temperature-dependent
manner by clathrin-mediated endocytosis. (A) This uptake and
cross-presentation of uBZLF1-derived epitopes is inhibited at 4uC. PBMC
were pulsed for 2 h at 4uCo r3 7 uC with uBZLF1 or RAK peptide. The
number of BZLF1-specific lymphocytes was determined by ELISpot. (B)
Cross-presentation of uBZLF1 is blocked by sucrose, an inhibitor of
clathrin-mediated endocytosis. Donor PBMC were stimulated with
either uBZLF1 or the RAK peptide in presence of the indicated
concentrations sucrose and the frequency of IFN-c secreting cells was
analyzed. Sucrose did not exhibit cytotoxic effects on PBMC at the used
concentrations, as shown by PI-staining. All ELISpot data show mean
SFC values+s.d. of 5 replicate stimulations and are representative of
results performed with PBMC of 2 different individuals.
doi:10.1371/journal.ppat.1000198.g004
Urea-Mediated Cross-Presentation
PLoS Pathogens | www.plospathogens.org 6 November 2008 | Volume 4 | Issue 11 | e1000198Figure 5. uBZLF1 is processed by a cross-presentation pathway. Cross-presentation of uBZLF1 is not influenced by (A) inhibition of
endolysosomal acidification using chloroquine or NH4Cl, (B) but is significantly abrogated in presence of the proteosomal inhibitors epoxomycine and
lactacystine. The ELISpot data show mean SFC values+s.d. of 5 replicate stimulations and are representative of results performed with PBMC of 3
different individuals. None of the applied drugs exhibited cytotoxic effects on PBMC at the used concentrations, as shown by PI-staining. (C) BFA
strongly inhibits cross-presentation of uBZLF1. Whole blood was stimulated with uBZLF, RAK-peptide or, as control, 0.04 M urea in presence or
absence of BFA. IFN-c production was analyzed by intracellular staining using flow cytometry. The data show the number of specifically reactivated
IFN-c positive CD8
+ T cells and are representative of experiments performed with 3 different donors.
doi:10.1371/journal.ppat.1000198.g005
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20 mM Bis-Tris propane (BTP), 5 mM EDTA, 100 mM NaCl,
pH 7.0; BZLF1D176–189: 20 mM Tris-HCl, 1 mM EDTA, 50 mM
NaCl, pH 7.5). Cells were lysed by two passages through the high
pressure Basic-Z system (IUL Instruments) at 1,500 bar. To avoid
DNA contamination crude extracts were incubated with 2 U/ml
Benzonase (20 min, RT). Subsequently, cell lysates were cleared
by centrifugation (30,000 g, 10 min, 4uC).
Forpurificationoffull-lengthBZLF1,insolubleBZLF1precipitate
was washed (2 M urea, 20 mM BTP, 50 mM NaCl, pH 7.0) and
then solubilized overnight in buffer containing 4 M urea (100 mM
Tris, 4 M urea, 2 mM DTT, pH 7.5, overnight). After precipitation
(30,000 g, 20 min), supernatant was further purified from contam-
inatingproteinsviaacidprecipitation.Therefore,pHwasadjustedto
3.5 by addition of 1N HCl and further incubated for 30 min.
Precipitated proteins were removed by centrifugation and BZLF1
containing supernatant was dialyzed (4 M urea, 20 mM citric acid,
pH 3.5) and then loaded on a cation exchange column (Source S
(GEHealthcareLifeSciences)).BZLF1containing fractionseluted at
,500 mM NaCl. BZLF1 containing fractions were pooled, dialyzed
against (4 M urea, 20 mM Tris-HCl, 2 mM DTT, pH 7.5) and
further purified by anion exchange chromatography (Source Q (GE
Healthcare Life Sciences)). Pooled BZLF1 containing fraction (75–
150 mM NaCl) was finally purified by gel filtration (Superdex 75
(GE Healthcare Life Sciences)).
For purification of truncated BZLF1D176–189, BZLF1D176–189
was first precipitated by dialysis against 4 M urea, 20 mM formic
acid, 50 mM NaCl, 1 mM EDTA, pH 4.0. After centrifugation
(17,000 g, 15 min) BZLF1D176–189 was resolubilized by dialysis
(6 M urea, 50 mM formic acid, 50 mM NaCl, pH 4.0). Soluble
denatured BZLF1D176–189 containing fraction was loaded on a
cation exchange column (Source Q (GE Healthcare Life
Sciences)). Pooled BZLF1D176–189 fraction (300–600 mM NaCl)
was neutralized (4 M urea, 20 mM Tris-HCl, 2 mM DTT,
pH 7.5) and further purified by anion exchange chromatography
(Source Q (GE Healthcare Life Sciences)). Finally, BZLF1D176–189
fraction (,100 mM NaCl) was purified by gel filtration (Superdex
75 (GE Healthcare Life Sciences)) chromatography for removal of
further protein contamination from the expression host.
Resulting full-length BZLF1 and truncated BZLF1D176–189
revealed a purity of .95%. BZLF1 or BZLF1D176–189 were
adjusted to a final concentration of 1 mg/ml in 4 M urea with
2 mM DTE prior to use in stimulation experiments.
Cell preparation
Whole blood was obtained from healthy EBV seropositive
volunteers with known HLA compositions. The study was
approved by the Institutional Ethics Committee. PBMC were
prepared from heparinized blood by standard Ficoll-Paque (PAN)
density centrifugation, washed twice in PBS, resuspended in
RPMI-1640 medium containing 10% (vol/vol) human AB-serum
and 1% (vol/vol) antibiotics (streptomycin 10 mg/ml; penicillin
10 mg/ml) and adjusted to 1610
7 cells/ml. B cells and monocytes
were purified from peripheral blood by MACS Sort magnetic
beads through positive selection using anti-CD19 and anti-CD14
antibodies in MACS LS separation columns (Miltenyi Biotech)
according to the manufacturer’s protocol. Cell purity was assessed
by flow cytometry using anti-CD20 (clone M5E2) and anti-CD14
(clone 2H7) (BD) antibodies. Production and phenotypical
characterization of immature and mature dendritic cells was
performed as previously described [52]. The purity of the APC
populations was beyond 98%.
Figure 6. iDC, mDC, monocytes and B cells are capable to process uBZLF1 for epitope-presentation to CTL. iDC, mDC, monocytes, and
B cells from EBV-seropositive, HLA B8-positive individuals were incubated for 2 h with 10 mg/ml uBZLF1, RAK or the E10F control peptide, washed
and co-cultured with autologous PBMC at the indicated ratios. Numbers of positive cells were determined by ELISpot. The data show mean SFC
values+s.d. of 5 replicate stimulations and are representative for 3 independent experiments with different donors.
doi:10.1371/journal.ppat.1000198.g006
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IFN-c ELISpot assays were performed as described previously
[53]. Briefly, 2610
5 PBMC were plated in 5 replicates into 96-well
ELISpot plates (MAHA N45, Millipore) pre-coated with anti-IFN-c
mAb 1D-1K (5 mg/ml) (MabTech) and stimulated overnight at
37uC. After removal of the cells, the plates were developed with the
IFN-c specific biotinylated antibody 7-B6-1 (1 mg/ml) (MabTech)
and streptavidine-alkaline phosphatase. Visualization of spots was
performed with nitroblue tetrazolium substrate solution (Roche).
IFN-c SFC were counted with a Bioreader 2000 (ByoSys).
Flow cytometry analysis of intracellular cytokines
For intracellular cytokine staining, heparinized whole blood from
healthy EBV positive donors was incubated for 7 h at 37uC, the last
4 h in presence of 10 mg/ml BFA (Sigma), with either 10 mg/ml of
theindicatedantigensor0.04 Murea-bufferascontrol.Anti-CD49d
and anti-CD28 monoclonal antibodies (BD) were added for co-
stimulation according to the manufacturer’s protocol. The following
reagents were used for flow cytometric analysis, unless otherwise
noted: fluorescein isothiocyanate (FITC)-conjugated anti-CD8
(clone B9.11), phycoerythrin-texas-red (ECD)-conjugated anti-CD3
(clone UCHT1), cychrome
TM (Pc5)-labelled anti-CD4 (clone
13B8.2) and a phycoerythrin (PE)-conjugated anti-IFN-c antibody
(clone 45.15) (all Beckman Coulter). Intracellular and surface
markers were stained following fixation and permeabilisation of
cells. Stained cells were run on a FACS Epics XL MCL flow
cytometer(BeckmanCoulter).Live-gatingoflymphocytesand CD3
+
events was performed during acquisition. Up to 2610
6 events were
acquired for each analysis. Results were reported as percentage of
the gated population producing IFN-c.
Antigen presentation assays and inhibitory compounds
Pure APC populations were pulsed with 10 mg/ml uBZLF1 or
RAK peptide for 2 h at 37uC, washed twice and co-cultured with
autologous PBMC for 20 h. For the analysis of the presentation
pathway of uBZLF1, the following inhibitory compounds were
used at indicated concentrations: sucrose, epoxomicin, lactacystin,
NH4Cl, chloroquine (all from Sigma). The working concentration
of BFA (Sigma) was 10 mg/ml. In antigen processing and
presentation assays, PBMC or whole blood samples were pre-
treated with the respective inhibitory compounds 45 min prior to
pulsing with the indicated antigens. The compounds remained in
the culture throughout the incubation. The number of IFN-c
producing cells was assessed by ELISpot after stimulation of
PBMC for 20 h or by FACS analysis following stimulation of
whole blood for 7 h, respectively. Cell viability was analyzed by
staining with propidium iodide (BD), according to the manufac-
turer’s protocol.
Statistical analysis
Statstical analysis was evaluated using the Mann-Whitney U-test
in SPSS for independent samples. A value of p,0.05 was
considered significant.
Accession numbers
The accession number of the BZLF1 protein used in this study is
YP_401673.
Supporting Information
Figure S1 Numbers and ratios of specifically reactivated CD8
+
T cells and Th cells differ in uBZLF1, BZLF1 and RAK peptide
stimulated blood cells of individual donors. Heparinized blood
samples of four to six different HLA B8, EBV-seropositive donors
were pulsed with 10 mg/ml uBZLF1, dialyzed BZLF1 or RAK
peptide and the percentage of IFN-c positive Th cells and CD8
+ T
cells was assessed by flow cytometry. In these experiments we
observed substantial differences in the total numbers and ratio of
specifically reactivated CD8
+ T cells upon stimulation with
uBZLF1 and RAK. The removal of urea from uBZLF1 by
extensive dialysis results in an almost complete loss of its capacity
to restimulate CD8
+ T cell (donor 1 to 4). Furthermore uBZLF1
stimulation of whole blood activated only limited (donor 1, 2) to
undetectable (donors 3 to 6) numbers of Th cells for IFN-c
production. NT: not tested.
Found at: doi:10.1371/journal.ppat.1000198.s001 (0.64 MB TIF)
Figure S2 (u)pp65 (4 M urea) but not urea-free pp65 reactivates
specific CD8
+ T lymphocytes as determined by intracellular IFN-c
staining. In contrast, removal of urea from upp65 had no effect on
its ability to specifically restimulate CD4
+ T cells. Whole blood
from a CMV-seropositive donor was stimulated with either 10 mg/
ml of pp65, upp65 or for control with 0.04 M urea. Cells were
incubated for 7 h at 37 Cu with 10 mg/ml BFA added for the last
4 h. Shown is the percentage of CD3
+CD8
+ or CD3
+CD4
+ cells
expressing IFN-c from a representative stimulation of three
independent experiments using different donors. Plots show log
fluorescence intensity.
Found at: doi:10.1371/journal.ppat.1000198.s002 (1.42 MB TIF)
Figure S3 Urea does not induce secretion of cytokines from
PBMC. PBMC were incubated with 0.04 M urea solution. Cells
stimulated with medium alone, 100 ng/ml lipopolysaccharide
(LPS) or 1 mg/ml phorbol 12-myristate 13-acetate (PMA)/
Ionomycin served as negative and positive controls. After 24 h
cell-free supernatants were collected and analyzed for depicted
cytokines using a Luminex 100
TM and the Human UltraSensitive
Cytokine Ten-Plex Antibody Bead Kit. Values exceeding the
detection limit are indicated by asterisks. The data represent mean
values of two independent stimulations +s.d.
Found at: doi:10.1371/journal.ppat.1000198.s003 (1.43 MB TIF)
Figure S4 Urea does not activate dendritc cells. iDC were
generated by cultivation of monocytes in the presence of 500 mg/
ml GM-CSF and IL-4 for 5 days. iDC were stimulated for
48 hours with 0.04 M urea solution and anayzed for the
expression of costimulatory molecules and HLA-DR by flow
cytometry. Cells stimulated with medium alone, 100 ng/ml LPS
or Ionuleit cocktail (10 ng/ml IL-1b, 10 ng/ml TNFa, 1000 U/
ml IL-6, 1 mg/ml PGE2) served as negative and positive controls.
The data shown are representative of 2 independent experiments
with iDC of different donors.
Found at: doi:10.1371/journal.ppat.1000198.s004 (2.02 MB TIF)
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